Diabetic Foot Ulcer Healing by Load Relieving Dressings

Information

  • Research Project
  • 7065182
  • ApplicationId
    7065182
  • Core Project Number
    R44DK062547
  • Full Project Number
    5R44DK062547-03
  • Serial Number
    62547
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/2002 - 22 years ago
  • Project End Date
    4/30/2008 - 16 years ago
  • Program Officer Name
    JONES, TERESA L. Z.
  • Budget Start Date
    5/1/2006 - 18 years ago
  • Budget End Date
    4/30/2008 - 16 years ago
  • Fiscal Year
    2006
  • Support Year
    3
  • Suffix
  • Award Notice Date
    3/16/2006 - 18 years ago
Organizations

Diabetic Foot Ulcer Healing by Load Relieving Dressings

DESCRIPTION (provided by applicant): In the US more than 80,000 lower extremity amputations are performed in diabetic patients per year. Foot ulcers are much more common and the path to most amputations starts with an ulcer. The health care cost of these problems has been estimated to be almost $11 billion per year. The longer an ulcer stays open, the more likely it is to get infected and lead to an amputation. "Usual care" heals typically only about 30% of ulcers in 20 weeks, yet a total contact cast (TCC) can heal > 90% of ulcers in an average of 8 weeks. The main advantage of the TCC over other approaches is that it mechanically off-loads the wound and, since it cannot be removed by the patient, does so without need for patient compliance. Despite its significant superiority over "usual care" in terms of efficacy, acceptance of the TCC by providers is poor and thus efficacious alternatives must be found. Under the completed phase I SBIR we have demonstrated feasibility of a prototype Load Relieving Dressing (LRD) that also does not demand complete patient compliance. We have developed second generation prototypes which show off-loading equivalent to that of a TCC and we have begun testing in actual patients. We are also negotiating an agreement with a major dressing manufacturer which could lead to licensing of the final product. Under this phase II proposal we will refine the design of the LRD to facilitate its application to the wound site while maintaining optimal off-loading and ensuring patient compliance. In addition we will perform a randomized controlled trial of the LRD testing the hypothesis that the LRD will be equivalent in terms of clinical outcomes to the TCC in the treatment of patients with neuropathic foot ulcers. This product not only has commercial potential, but also offers the possibility of putting a tool into the hands of providers which could heal many ulcers faster than is usual at present and could therefore prevent many lower extremity amputations.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R44
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    653354
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:653354\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    DIAPEDIA, LLC
  • Organization Department
  • Organization DUNS
  • Organization City
    STATE COLLEGE
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    16801
  • Organization District
    UNITED STATES